(Q74660334)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9630088%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

review article

1 reference

title

Current medical therapy for advanced heart failure (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9630088%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

1 reference

M Gheorghiade

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9630088%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

R J Cody

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9630088%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

G S Francis

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9630088%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

W J McKenna

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9630088%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

J B Young

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9630088%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

R O Bonow

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9630088%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

language of work or name

English

0 references

publication date

1 June 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9630088%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

published in

American Heart Journal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9630088%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

volume

135

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9630088%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

issue

6 Pt 2 Su

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9630088%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

page(s)

S231-48

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9630088%20AND%20SRC:MED&resulttype=core&format=json

Heart failure: a growing public health problem

12 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

The Natural History of Congestive Heart Failure: The Framingham Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

The epidemiology of heart failure: the Framingham Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Prevalence and mortality rate of congestive heart failure in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Heart failure in the United States 1970-1985.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

The effect of digoxin on mortality and morbidity in patients with heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Heart failure in the 1990s: evolution of a major public health problem in cardiovascular medicine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Estimating severity of chronic heart failure: A clinical challenge for the 1990s

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Natural history and patterns of current practice in heart failure. The Studies of Left Ventricular Dysfunction (SOLVD) Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Systolic function, readmission rates, and survival among consecutively hospitalized patients with congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Congestive heart failure with normal systolic function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Intact systolic left ventricular function in clinical congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Hospitalized congestive heart failure patients with preserved versus abnormal left ventricular systolic function: clinical characteristics and drug therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Epidemiology of heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Survival after the onset of congestive heart failure in Framingham Heart Study subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Sudden death prevention in patients with advanced ventricular dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Chronic heart failure in the United States: a manifestation of coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Management of refractory congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

The management of chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Left ventricular shape as a determinant of functional mitral regurgitation in patients with severe heart failure secondary to either coronary artery disease or idiopathic dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Relation of left ventricular chamber shape in patients with low (≤40%) ejection fraction to severity of functional mitral regurgitation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

The role of subendocardial ischemia in perpetuating myocardial failure in patients with nonischemic congestive cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Long-term predictors of sudden and low output death in chronic congestive heart failure secondary to coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Vascular biology and medicine in the 1990s: scope, concepts, potentials, and perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

The dysfunctional endothelium in heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Myocardial endothelin. Does it play a role in myocardial failure?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Endothelium-derived contracting factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Effects of afterload reduction (diuretics and vasodilators) on left ventricular volume and mitral regurgitation in severe congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Left ventricular shape, afterload and survival in idiopathic dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Importance of hemodynamic response to therapy in predicting survival with ejection fraction less than or equal to 20% secondary to ischemic or nonischemic dilated cardiomyopathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Improving survival for patients with advanced heart failure: A study of 737 consecutive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Obstructive sleep apnoea in patients with dilated cardiomyopathy: effects of continuous positive airway pressure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Acute effects of digoxin on total systemic vascular resistance in congestive heart failure due to dilated cardiomyopathy: a hemodynamic-hormonal study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Hemodynamic effects of intravenous digoxin in patients with severe heart failure initially treated with diuretics and vasodilators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Comparative hemodynamic and neurohormonal effects of intravenous captopril and digoxin and their combinations in patients with severe heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Long-term digitalis therapy improves left ventricular function in heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Digoxin. A neurohormonal modulator in heart failure?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Effect of long-term digoxin therapy on autonomic function in patients with chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Heart rate variability in patients with mild to moderate heart failure: effects of neurohormonal modulation by digoxin and ibopamine. The Dutch Ibopamine Multicenter Trial (DIMT) Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Sympathoinhibitory responses to digitalis glycosides in heart failure patients. Direct evidence from sympathetic neural recordings.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

The effect of different digoxin doses on subjective symptoms and physical working capacity in patients with atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

A controlled trial of digoxin in congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Review of randomized trials of digoxin therapy in patients with chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Patients with mild heart failure worsen during withdrawal from digoxin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Digitalis Investigation Group (DIG) trial: a stimulus for further research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Does digoxin provide additional hemodynamic and autonomic benefit at higher doses in patients with mild to moderate heart failure and normal sinus rhythm?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Digoxin reduces cardiac sympathetic activity in severe congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Effects of increasing maintenance dose of digoxin on left ventricular function and neurohormones in patients with chronic heart failure treated with diuretics and angiotensin-converting enzyme inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Ischemia-induced alterations in myocardial (Na+ + K+)-ATPase and cardiac glycoside binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Facilitation of lethal ventricular arrhythmias by therapeutic digoxin in conscious post infarction dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Reduction in digitalis-associated postinfarction mortality with nadolol in conscious dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Cardiac and peripheral vascular effects of digitalis in clinical cardiogenic shock.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Quinidine-digoxin interaction: Pharmacokinetics, underlying mechanism and clinical implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Effects of verapamil on pharmacokinetics and pharmacodynamics of digitoxin in patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Amiodarone increases plasma digoxin concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Clarithromycin-related toxic effects of digoxin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Pharmacokinetic interactions between digoxin and other drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Double-blind comparison of captopril alone against frusemide plus amiloride in mild heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Management of heart failure. I. Pharmacologic treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Clinical pharmacology of torasemide, a new loop diuretic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

The physiologic basis of diuretic synergism: its role in treating diuretic resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Captopril and spironolactone therapy for refractory congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Furosemide absorption altered in decompensated congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

The effects of frusemide and angiotensin-converting enzyme inhibitors and their combination on cardiac and renal haemodynamics in heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Metolazone in treatment of severe refractory congestive cardiac failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Direct myocardial and coronary effects of enalaprilat in patients with dilated cardiomyopathy: assessment by a bilateral intracoronary infusion technique.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Influence of severity of heart failure on the efficacy of angiotensin-converting enzyme inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Pharmacotherapy for systolic dysfunction: a review of randomized clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Hyponatraemia as a marker for high renin heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Effects of two different enalapril dosages on clinical, haemodynamic and neurohumoral response of patients with severe congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

ACE inhibitors for heart failure: a question of dose

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Use of 'Xapril' in patients with chronic heart failure. A paradigm or epitaph for our times?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Nitrates are effective in the treatment of chronic congestive heart failure: the protagonist's view

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Improved exercise capacity and differing arterial and venous tolerance during chronic isosorbide dinitrate therapy for congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Tolerance to organic nitrates: evidence, mechanisms, clinical relevance, and strategies for prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Hydralazine in the long-term treatment of chronic heart failure: lack of difference from placebo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Clinical efficacy of hydralazine in chronic heart failure: one-year double-blind placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Concurrent hydralazine administration prevents nitroglycerin-induced hemodynamic tolerance in experimental heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Vasodilator therapy in refractory congestive heart failure: a comparative analysis of hemodynamic and noninvasive studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Provocation of myocardial ischemic events during initiation of vasodilator therapy for severe chronic heart failure. Clinical and hemodynamic evaluation of 52 consecutive patients with ischemic cardiomyopathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Rest and exercise hemodynamic effects of oral hydralazine in patients with coronary artery disease and left ventricular dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Hemodynamic responses to combined therapy with captopril and hydralazine in patients with severe heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Beta-adrenergic blockers and survival in heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Calcium channel blockers and congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Calcium channel blockers in heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

The effect of diltiazem on mortality and reinfarction after myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Clinical and neurohormonal effects of nicardipine hydrochloride in patients with severe chronic heart failure receiving angiotensin-converting enzyme inhibitor therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II--DAVIT II)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

The design of the Mortality Assessment in Congestive Heart Failure Trial (MACH-1, mibefradil).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

The development of positive inotropic agents for chronic heart failure: how have we gone astray?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Intermittent inotropic therapy in an outpatient setting: a cost-effective therapeutic modality in patients with refractory heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

The hibernating myocardium: implications for management of congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Low-dose dobutamine in patients with acute myocardial infarction identifies viable but not contractile myocardium and predicts the magnitude of improvement in wall motion abnormalities in response to coronary revascularization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Differing autonomic response to dobutamine in the presence and absence of ischemia: implications for the autonomic contribution to positive inotropic intervention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Recruitment of an inotropic reserve in moderately ischemic myocardium at the expense of metabolic recovery. A model of short-term hibernation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Development of short-term myocardial hibernation. Its limitation by the severity of ischemia and inotropic stimulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Hibernating myocardium: an incomplete adaptation to ischemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Inotropic stimulation by dobutamine increases left ventricular regional function at the expense of metabolism in hibernating myocardium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Incremental Doses of Dobutamine Induce a Biphasic Response in Dysfunctional Left Ventricular Regions Subtending Coronary Stenoses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Arrhythmia suppression in postmyocardial infarction patients with special notation to cardiac arrhythmia suppression trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Amiodarone therapy in chronic heart failure and myocardial infarction: a review of the mortality trials with special attention to STAT-CHF and the GESICA trials. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Heart rate is a marker of amiodarone mortality reduction in severe heart failure. The GESICA-GEMA Investigators. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina-Grupo de Estudios Multicéntricos en Argentina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Amiodarone: reevaluation of an old drug

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

High dose oral amiodarone loading exerts important hemodynamic actions in patients with congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Low-dose amiodarone for atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Unsustained ventricular tachycardia--to treat or not to treat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

The effect of warfarin on mortality and reinfarction after myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

American College of Cardiology 45th Annual Scientific Session, Orlando, Florida, March 24 to 27, 1996.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Adverse effect of warfarin in acute myocardial infarction: increased left ventricular thrombus formation in patients not treated with high-dose heparin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Effect of antithrombotic therapy on risk of sudden coronary death in patients with congestive heart failure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Warfarin anticoagulation and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

The heart failure epidemic: magnitude of the problem and potential mitigating approaches.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970253-4

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-8703(98)70253-4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9630088%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

1 reference